...
首页> 外文期刊>Daru Journal of pharmaceutical sciences. >Systematic protein-protein docking and molecular dynamics studies of HIV-1 gp120 and CD4: insights for new drug development
【24h】

Systematic protein-protein docking and molecular dynamics studies of HIV-1 gp120 and CD4: insights for new drug development

机译:HIV-1 gp120和CD4的系统蛋白-蛋白对接和分子动力学研究:新药开发的见解

获取原文
           

摘要

Background and the purpose of the studyThe interactions between HIV-1 gp120 and mutated CD4 proteins were investigated in order to identify a lead structure for therapy based on competitive blocking of the HIV binding receptor for human T-cells. Crystal structures of HIV gp120-CD4 complexes reveal a close interaction of the virus receptor with CD4 Phe43, which is embedded in a pocket of the virus protein.MethodsThis study applies computer simulations to determine the best binding of amino acid 43 CD4 mutants to HIV gp120. Besides natural CD4, three mutants carrying alternate aromatic residues His, Trp and Tyr at position 43 were investigated. Several docking programs were applied on isolated proteins based on selected crystal structures of gp120-CD4 complexes, as well as a 5 ns molecular dynamics study on the protein complexes. The initial structures were minimized in Gromacs to avoid crystal packing effects, and then subjected to docking experiments using AutoDock4, FireDock, ClusPro and ZDock. In molecular dynamics, the Gibbs free binding energy was calculated for the gp120-CD4 complexes. The docking outputs were analyzed on energy within the respective docking software.Results and conclusionVisualization and hydrogen bonding analysis were performed using the Swiss-PdbViewer. Strong binding to HIV gp120 can be achieved with an extended aromatic group (Trp). However, the sterical demand of the interaction affects the binding kinetics. In conclusion, a ligand for an efficient blocking of HIV gp120 should involve an extended but conformational flexible aromatic group, i.e. a biphenyl. A docking study on biphenylalanine-43 confirms this expectation.
机译:研究的背景和目的研究了HIV-1 gp120与突变的CD4蛋白之间的相互作用,以基于竞争性阻断人类T细胞的HIV结合受体来确定治疗的先导结构。 HIV gp120-CD4复合物的晶体结构揭示了病毒受体与嵌入在病毒蛋白口袋中的CD4 Phe43的紧密相互作用。 。除天然CD4外,还研究了在第43位带有交替的芳香族残基His,Trp和Tyr的三个突变体。根据gp120-CD4复合物的选定晶体结构,对分离的蛋白质应用了几种对接程序,并对该蛋白质复合物进行了5 ns的分子动力学研究。在Gromacs中将初始结构最小化以避免晶体堆积效应,然后使用AutoDock4,FireDock,ClusPro和ZDock进行对接实验。在分子动力学中,计算了gp120-CD4复合物的吉布斯自由结合能。对接输出在各自的对接软件中进行了能量分析。结果和结论使用Swiss-PdbViewer进行了可视化和氢键分析。可以通过扩展的芳香族基团(Trp)实现与HIV gp120的强结合。但是,相互作用的空间需求会影响结合动力学。总之,有效阻断HIV gp120的配体应包括一个扩展但构象的柔性芳族基团,即联苯。对联苯丙氨酸43的对接研究证实了这一期望。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号